Inventiva: Canaccord Genuity raises target

(CercleFinance.com) - Canaccord Genuity reaffirms its 'buy' recommendation on Inventiva, with a price target raised from $12 to $20, mainly due to an adjustment of the estimated pricing for lanifibranor, the biopharmaceutical company's lead drug candidate.


The Canadian broker adds that it has pushed back the anticipated launch year for this product on the US market from 2026 to 2027, given the completion of enrolment scheduled for the first half of 2024 and the 72-week duration of the study.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.